(Q36484894)

14 August 2017

1 reference

title

Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension (English)

1 reference

14 August 2017

main subject

arterial hypertension

0 references

author name string

Anna R Hemnes

series ordinal

1

1 reference

14 August 2017

Hunter C Champion

series ordinal

2

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Expert Review of Cardiovascular Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

4

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

293-300

1 reference

Clinical classification of pulmonary hypertension.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Primary pulmonary hypertension in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Tissue expression, distribution, and regulation of PDE5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil inhibits hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Oral sildenafil reduces pulmonary hypertension after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Novel use of sildenafil in the treatment of portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Oral sildenafil for treatment of severe pulmonary hypertension in an infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Use of oral sildenafil in patients with irreversible pulmonary hypertension not eligible for heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Portopulmonary hypertension and hepatopulmonary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

The mechanism of cGMP-induced relaxation in vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.293

21 January 2018

Identifiers

DOI

10.1586/14779072.4.3.293

1 reference

14 August 2017

1 reference